Evaluating the use of lutetium vipivotide tetraxetan in advanced prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather real-world data on the use of lutetium (177Lu) vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC). It will assess health-related quality of life (HRQoL) at various stages: before treatment, during treatment, at the end of treatment, and during follow-up. Data will be collected through patient questionnaires over a period of up to one year after treatment. The study will involve adult male patients who are starting this treatment as per their physician's decision.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All patients must meet the following inclusion criteria during the identification period:

* Adult male patients diagnosed with mCRPC and initiating lutetium (177Lu) vipivotide tetraxetan by treating physician as per local label. After treatment decision enrollment is allowed before date of cycle 1 or within 2 weeks after the date of Cycle 1.
* ≥ 18 years old at the time of enrollment
* Written informed consent must be obtained prior to any data collection
* Willing to participate in Quality of Life post treatment date collection for 1 year

Exclusion Criteria:

Patients must not meet the following exclusion criterion during the identification period:

\- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with lutetium (177Lu) vipivotide tetraxetan

Where it's running

• Novartis Investigative Site
  Konstanz, Baden-Wurttemberg, Germany Recruiting
• Novartis Investigative Site
  Stuttgart, Baden-Wurttemberg, Germany Recruiting
• Novartis Investigative Site
  Munich, Bavaria, Germany Recruiting
• Novartis Investigative Site
  Regensburg, Bavaria, Germany Recruiting
• Novartis Investigative Site
  Würzburg, Bavaria, Germany Recruiting
• Novartis Investigative Site
  Cottbus, Brandenburg, Germany Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JUR-003 in adults with advanced prostate cancer

  This first-in-human study tests JUR-003 to see if it is safe and tolerable and to get an early sense of activity in adults with metastatic or advanced prostate cancer.

  Recruiting at 4 sites Phase 1 TCG Labs Soleil · Grand Rapids, Michigan and 3 other locations · NCT07824349

• SRT-017 radioligand therapy in PSMA-positive metastatic castration-resistant prostate cancer

  This study tests SRT-017 given by IV infusion to men with PSMA-positive metastatic castration-resistant prostate cancer to see if it is safe and tolerable and to gather early signals of anti-tumor activity.

  Recruiting Early Phase 1 Affiliated Hospital of Jiangnan University · Wuxi, Jiangsu · NCT07798778

• Rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer after abiraterone failure

  This study tests whether adding rinzimetostat to darolutamide helps people with metastatic castration-resistant prostate cancer who previously took abiraterone.

  Recruiting at 15 sites Phase 3 ORIC Pharmaceuticals · Glendale, California and 14 other locations · NCT07723248

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Dual-target PSMA/PSCA CAR-NK Therapy in Advanced Prostate Cancer

  This trial tests ETB-DualNK-01, a dual-target CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer to see if it is safe and shows early signs of activity.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07641049

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.